Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E16.06 EPS (ttm)21.02 Insider Own0.41% Shs Outstand201.40M Perf Week4.04%
Market Cap67.98B Forward P/E12.06 EPS next Y27.98 Insider Trans-0.12% Shs Float200.66M Perf Month5.44%
Income4.36B PEG2.06 EPS next Q6.71 Inst Own91.20% Short Float1.90% Perf Quarter1.99%
Sales13.23B P/S5.14 EPS this Y3.00% Inst Trans0.17% Short Ratio2.76 Perf Half Y-4.39%
Book/sh68.35 P/B4.94 EPS next Y8.39% ROA12.90% Target Price385.37 Perf Year0.47%
Cash/sh21.99 P/C15.35 EPS next 5Y7.78% ROE24.20% 52W Range249.17 - 388.67 Perf YTD12.17%
Dividend- P/FCF11.71 EPS past 5Y24.80% ROI21.90% 52W High-14.27% Beta1.14
Dividend %- Quick Ratio2.50 Sales past 5Y17.30% Gross Margin86.10% 52W Low33.73% ATR9.70
Employees7300 Current Ratio2.70 Sales Q/Q11.70% Oper. Margin44.70% RSI (14)63.64 Volatility1.96% 3.31%
OptionableYes Debt/Eq0.43 EPS Q/Q23.60% Profit Margin24.10% Rel Volume0.70 Prev Close337.54
ShortableYes LT Debt/Eq0.43 EarningsJan 29 BMO Payout0.00% Avg Volume1.38M Price333.21
Recom2.00 SMA207.98% SMA505.30% SMA2005.74% Volume596,583 Change-1.28%
Dec-21-18Initiated BTIG Research Buy
Oct-19-18Downgrade Bernstein Outperform → Mkt Perform
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
Aug-07-18Resumed Stifel Buy $394
Jul-25-18Reiterated SunTrust Buy $321 → $392
Jul-10-18Downgrade Robert W. Baird Outperform → Neutral
Jul-06-18Upgrade Citigroup Neutral → Buy
May-31-18Upgrade Canaccord Genuity Hold → Buy $350 → $335
Apr-25-18Upgrade Robert W. Baird Neutral → Outperform
Apr-05-18Downgrade Barclays Overweight → Equal Weight $395 → $295
Feb-16-18Downgrade Argus Buy → Hold
Feb-05-18Reiterated Mizuho Buy $400 → $433
Jan-26-18Reiterated H.C. Wainwright Buy $340 → $363
Jan-24-18Reiterated Canaccord Genuity Hold $340 → $350
Jan-17-18Reiterated Canaccord Genuity Hold $340 → $350
Dec-22-17Reiterated Nomura Buy $355 → $420
Dec-20-17Upgrade Credit Suisse Neutral → Outperform
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Jan-16-19 12:08PM  REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily
Jan-14-19 04:22PM  Will Biogen Jump On This Biotech Stock Amid Buying Spree? Investor's Business Daily
Jan-10-19 04:14PM  Biogen Could Spend Nearly $18 Billion In A Takeover But Will It? Investor's Business Daily
Jan-09-19 12:29PM  Value Added: 7 Top Stocks for 2019 Kiplinger
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 02:41PM  The 10 Best Health-Care Stocks to Buy for 2019 Kiplinger
Jan-07-19 03:51PM  Biogen Inks Two Deals to Make Drugs for Neurological Diseases Zacks
Jan-06-19 07:24PM  BRIEF-Samsung Biologics JV Samsung Bioepis Partners With Chinese Biopharma 3SBio Reuters
10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
Jan-04-19 06:13PM  Biogen Begins Improved Dosing Regimen on Tysabri in Phase III Zacks
11:18AM  Biogen doubles down on Alzheimer's with new collaboration deal American City Business Journals
07:31AM  Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets PR Newswire
07:30AM  Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions GlobeNewswire
06:48AM  Are Biogen Inc.s (NASDAQ:BIIB) Interest Costs Too High? Simply Wall St.
Jan-03-19 07:30AM  First Patient Enrolled in Biogens Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis GlobeNewswire
Jan-02-19 04:28PM  Biopharmas Restrained In Drug Pricing For 2019 With These Exceptions Investor's Business Daily
06:00AM  Top Picks 2019- Ionis Pharmaceuticals IONS MoneyShow
Dec-27-18 01:50PM  The Humira Overhang Cant Cast a Shadow on AbbVie Stock Forever InvestorPlace
09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
08:47AM  Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears Zacks
Dec-26-18 02:22PM  6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +5.99%
Dec-24-18 10:04AM  Perrigo Plunges on $1.9B Tax Bill From Irish Government Zacks
Dec-21-18 04:26PM  Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug Investor's Business Daily
02:52PM  AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib Zacks
01:10PM  Perrigo Tumbles on $1.9 Billion Irish Tax Demand
12:55PM  Perrigo stock plunges toward biggest drop in 24 years after disclosing $1.9 billion Irish back-tax bill MarketWatch
Dec-20-18 09:44PM  U.S body says gene therapy may be more cost effective for spinal muscular atrophy Reuters
07:29PM  U.S body says gene therapy may be more cost effective for spinal muscular atrophy Reuters
04:13PM  6 Cheap Stocks Growing Earnings
12:19PM  Biogen Applauds Quebec Decision to Cover SPINRAZA (nusinersen) for a broad population of SMA Patients GlobeNewswire
02:52AM  [$$] Pharma Giants Plan Drug Price Hike: Report The Wall Street Journal
Dec-19-18 06:55AM  Today's Research Reports on Trending Tickers: Biogen and Biocept ACCESSWIRE
Dec-18-18 02:27PM  Biogen's Slump Is Likely to Continue -5.86%
11:55AM  Biotech Stocks Gilead Sciences and Biogen Have Room to Bounce Back
09:47AM  Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug Zacks
Dec-17-18 05:29PM  Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU Zacks
07:30AM  Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis GlobeNewswire
Dec-15-18 06:30AM  Better Buy: Biogen vs. Amgen Motley Fool
Dec-14-18 09:55AM  5 Incredible ETFs & Stocks to Buy on the Dip Zacks
08:23AM  5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019 Zacks
Dec-13-18 01:40PM  Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge? Benzinga
09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
07:56AM  The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen Benzinga
Dec-12-18 10:51AM  5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 InvestorPlace
10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
Dec-06-18 07:30AM  Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data GlobeNewswire
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks
Dec-03-18 09:00AM  AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018 Zacks
Nov-30-18 04:16PM  Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar Investor's Business Daily
Nov-29-18 11:45AM  How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big Investor's Business Daily
10:11AM  Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma Zacks
07:30AM  International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product GlobeNewswire
Nov-27-18 05:33PM  Health Care Stocks May Be Safe Haven in Event of Market Downturn
Nov-26-18 04:18PM  Hedge Funds Are Crazy About Biogen Inc. (NASDAQ:BIIB) Insider Monkey
Nov-23-18 11:11AM  US benefits manager baulks after Novartis values gene therapy at $4-5 mln Reuters
08:26AM  Why Biogen Inc (NASDAQ:BIIB) Looks Like A Quality Company Simply Wall St.
01:05AM  U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million Reuters
Nov-22-18 09:30AM  Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report? Zacks
Nov-21-18 09:47AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-14-18 03:09PM  Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels MarketWatch
06:11AM  [$$] Possible delisting of BioLogics threatens Samsungs growth strategy Financial Times
Nov-13-18 03:35PM  An expensive new medication is finally available for her rare disease but shes been fighting for two years to get it MarketWatch
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace
12:50PM  Ionis Pharmaceuticals Collects Royalties -- and Spends It All Motley Fool
Nov-09-18 11:02AM  6 Pharmaceutical Stocks to Buy After the Midterms InvestorPlace
Nov-08-18 04:11PM  Jeff Auxier Comments on Biogen
03:45PM  Jeff Auxier's Auxier Asset Management 3rd Quarter Commentary
Nov-07-18 03:43PM  7 Healthcare Stocks Soaring on Election Results InvestorPlace
Nov-06-18 05:48PM  Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript Motley Fool
Nov-05-18 02:28PM  Biogen Stock Rebounds After Impressive Q3 Earnings InvestorPlace
Nov-02-18 02:23PM  AbbVie sees hit to Humira sales from European competition Reuters
06:57AM  Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More Benzinga
Nov-01-18 03:34PM  Biotech ETFs in Focus on String of Q3 Earnings Beat Zacks
Oct-31-18 01:11PM  Sarissa Capitals Alex Denner Bullish on Biogen (BIIB) Insider Monkey
Oct-29-18 04:16PM  Biogen And Eisai May Be At Odds In Alzheimer's So What Now? Investor's Business Daily
08:20AM  New Research Coverage Highlights Rite Aid, The Boeing, Cabot, Biogen, McDonald's, and Pegasystems Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-28-18 09:56PM  Clearbridge Investments Betting On A Shift From Growth and Momentum Insider Monkey
12:31PM  This experimental Alzheimers disease drug seemed promising before the latest results left many unsure MarketWatch
Oct-26-18 11:55AM  The October stock crash has wiped out $45.5B from Mass. health firms American City Business Journals
10:45AM  Top Research Reports for McDonald's, Thermo Fisher & Caterpillar Zacks
09:15AM  Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimers Disease (CTAD) GlobeNewswire
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
Oct-25-18 04:07PM  Biogen Stock Dips After Alzheimer's Results Show 'Thin' Impact Investor's Business Daily
01:12PM  Eisai, Biogen Alzheimer's data fails to convince skeptics Reuters
11:01AM  Biogen analysts pounce on 'thin' Alzheimer's trial data American City Business Journals
10:51AM  Biogen shares slip after Alzheimer's data fails to convince Reuters
09:03AM  Biogen/Eisai Alzheimer's data suggests treatment effect related to drug Reuters
08:31AM  Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimers Disease at the 2018 Clinical Trials on Alzheimers Disease (CTAD) Conference GlobeNewswire
08:03AM  The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price Benzinga
Oct-24-18 03:07PM  Biogen Rides the Spinraza Wave to Double-Digit Growth Motley Fool
01:46PM  Alkermes Makes Financial Progress as Its Pipeline Moves Forward Motley Fool
11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks
11:11AM  Forward Pharma loses appeal in Tecfidera patent dispute with Biogen Reuters
10:53AM  Forward Pharma loses appeal in Tecfidera patent dispute with Biogen Reuters
10:20AM  Forward Pharma loses appeal in Tecfidera patent dispute with Biogen Reuters
02:45AM  Edited Transcript of BIIB earnings conference call or presentation 23-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
Oct-23-18 04:51PM  Biogen Tops Quarterly Views, But Shares Hamstrung On Pipeline 'Stumbles' Investor's Business Daily
03:17PM  Biogen Inc (BIIB) Q3 2018 Earnings Conference Call Transcript Motley Fool
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM
DENNER ALEXANDER JDirectorApr 25Buy269.9148,00012,955,680461,858Apr 27 07:48 AM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0053204,539Mar 05 04:41 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 27Sale290.8325975,3256,553Feb 28 05:39 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Option Exercise0.0046707,020Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.009204,772Feb 27 06:24 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 23Option Exercise0.00857025,225Feb 27 06:22 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Sale293.44908266,4446,553Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 22Option Exercise0.0019404,738Feb 26 04:11 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,63508,188Feb 26 04:12 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 22Option Exercise0.001,635025,095Feb 26 04:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 20Sale292.00743216,9566,553Feb 21 04:10 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,354010,233Feb 20 04:27 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,33909,186Feb 20 04:25 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,47204,854Feb 20 04:23 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,71205,407Feb 20 04:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 15Option Exercise0.0016104,600Feb 20 04:18 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 15Option Exercise0.001,712023,970Feb 20 04:17 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Sale298.851,294386,7127,296Feb 20 08:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.002,01208,565Feb 14 06:37 PM